Tuberculosis (TB) continues to be one of the deadliest infectious diseases in the world,
causing~ 1.5 million deaths every year. The World Health Organization initiated an End TB …

Introduction Tuberculosis (TB), one of the most common infectious diseases, requires
treatment with multiple antibiotics taken over at least 6 months. This long treatment often …

Background Given the persistently high global burden of tuberculosis, effective and shorter
treatment options are needed. We explored the relationship between relapse and treatment …

Introduction There is an urgent need for new anti-tuberculosis (TB) drugs and optimization of
current TB treatment. Moxifloxacin and linezolid are valuable options for the treatment of …

Granulomas are complex lung lesions that are the hallmark of tuberculosis (TB).
Understanding antibiotic dynamics within lung granulomas will be vital to improving and …

Background Moxifloxacin (MOX) is used as a first-choice drug to treat multidrug-resistant
tuberculosis (MDR-TB); however, evidence-based dosing optimization should be …

Background Improvement in tuberculosis treatment regimens requires selection of
antibiotics and dosing schedules from a large design space of possibilities. Incomplete …

Tuberculosis (TB) remains as one of the world's deadliest infectious diseases despite the
use of standardized antibiotic therapies. Recommended therapy for drug-susceptible TB is …

Background Levofloxacin is used for the treatment of multidrug-resistant tuberculosis;
however the optimal dose is unknown. Methods We used the hollow fiber system model of …

Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge
gained from preclinical investigations was not utilized to maximal effect. A mouse‐to‐human …